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Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb am-
putations. Despite widespread awareness of DN, the only effective treatments are glucose control and pain management. A grow-
ing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neuro-
trophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein 
or gene for therapy, but the effect was not significant. Recent studies have shown that bone marrow (BM)-derived stem or pro-
genitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells con-
tain various angiogenic and neurotrophic factors, these cells have been attempted for treating experimental DN, and turned out 
to be effective for reversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both 
vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN. 
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INTRODUCTION
Diabetic neuropathy (DN), a peripheral nervous system disor-
der, is the most common complication of diabetes mellitus 
(DM). Currently, about 23.6 million children and adults in the 
United States (around 8% of the population) are suffering from 
diabetes. About 60% of long-standing diabetic patients are af-
fected by DM. Patients with DN experience loss of sensation 
in areas of the body, reduced quality of life as a result of chron-
ic pain, and chronic wounds partly caused by impaired pain 
sensitivity. Autonomic nerve dysfunction also contributes to 
decreased quality of life in diabetic patients. DN can affect 
sensory, motor, and autonomic nerve fibers in any part of the 
body. The nerves of the lower extremities, having the longest 
nerve fibers, often develop symptoms first. There are many 
types of DM syndromes determined by the organ systems and 
types of nerves affected. Patients may be diagnosed with exclu-
sively sensorimotor or autonomic neuropathy or a combina-
tion of both. Severity of symptoms increases gradually over 
time and correlate with the degree of hyperglycemia [1].
 Currently, there are no clinically proven curative treatments 
for DN. Optimizing blood glucose control and foot care can 
halt disease progression, but they cannot cure already estab-
lished nerve damages which usually lead to secondary compli-
cations. Symptomatic treatment with pain medications is only 
partially effective and wounds are difficult to treat. Moreover, 
deficiency of neurotrophic factors has been regarded as one of 
the likely mechanisms underlying DN. In a clinical trial, a sin-
gle treatment of injected neurotrophic cytokines was ineffec-
tive for treating DN [2]. However, since DN is characterized 
by deficiency in angiogenic and neurotrophic factors, cell 
therapy has recently emerged as an attractive therapeutic strat-
egy for treating DN. 
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PATHOGENESIS OF DIABETIC NEUROPATHY
Although DN has been widely studied over the past 20 years 
and its pathology has been established (Fig. 1), the pathogene-
sis remains unclear. Known pathologies reported in diabetic 
patients include axonal atrophy, demyelination, nerve fiber 
loss, and blunted regeneration of nerves. Among many, two 
well-known pathogenesis was known for DN: metabolic ver-
sus vascular. Recent studies, however, have shown that both 
vascular factors and metabolic interactions are involved at all 
stages of DN. Erroneous glycemic control is clearly associated 
with the development of DN: both direct glucose measures 
and levels of glycated hemoglobin correlate with the occur-
rence of neuropathy. However, the cause of DN is more com-
plex than dysregulated glucose levels alone. Several contribut-
ing factors have been postulated and have received differing 
degrees of acceptance. Oxidative stress has been considered 
the final common pathway of cellular injury in hyperglycemia, 
but the mechanisms leading to DN are more complex, and an-
tioxidants alone do not prevent this disorder. Data from pre-
clinical and clinical studies show that in diabetes, oxidative 
and nitrosative stress are increased in plasma and tissues [3]. 
Reduced blood flow through loss of autonomic nerve func-
tions may contribute to the progression of DN, and alterations 
in microvessels, similar to the pathogenic neovascularization 
described in diabetic retinopathy and nephropathy.
Hyperglycemia
Excess intracellular glucose is processed by increased flux th r-
ough one or more glucose metabolism pathways, and pro-
longed hyperglycemia can lead to cellular damage in several 
ways. First, excess glycolysis can lead to overload of the mito-
chondrial electron transport chain and increased generation 
of reactive oxygen species (ROS). Second, abnormally increased 
polyol pathway activity increases cellular osmolality, reduces 
nicotinamide adenine dinucleotide phosphate (NADPH) levels, 
and leads to oxidative stress. Finally, increased flux through the 
hexosamine pathway is associated with inflammatory injury [4].
 Accumulation of ROS increases lipid, DNA, and protein 
peroxidation, induces cellular apoptosis, and reduces nerve 
blood flow (NBF). Increased oxidative stress leads to activa-
tion of the the polyADP-ribose polymerase (PARP) pathway, 
which regulates several inflammatory response gene expres-
sions and causes neuronal dysfunction. On a molecular level, 
the hyperglycemia is associated with five pathways: the polyol 
pathway; the advanced glycation end-product (AGE) path-
way; the protein kinase C pathway; the PARP pathway; and 
the hexosamine pathway. Studies suggest that oxidative stress 
and these five pathways are interdependent and essential to 
the pathogenesis of neurovascular dysfunction. On a cellular 
level, hyperglycemia affects sensory, motor, and autonomic 
neurons by activating the five pathways [5]. 
 In vivo studies show the induction of microvascular isch-
emia by reducing blood flow results in nerve dysfunction. 
ROS and reactive nitrogen species are inducing factors of mi-
crovascular complications of diabetes. ROS induces impair-
ment of vasodilation of epineural blood vessels, resulting in 
ischemia to the neural tissue. Oxidative stress also leads to de-
terioration of Schwann cells, which play a key role as a provid-
er of insulation for neurons, immunologic perineurial blood 
nerve barrier, and effector of nerve regeneration. Such dys-
function via elevated oxidative stress contributes to the pheno-
type of DN. Thus, antioxidants have become the therapeutic 
targets in DN studies. However, only a few studies have sug-
gested that antioxidants can prevent or reverse hyperglycemia-
induced nerve dysfunction in experimental DN models [6].
 Another consequence of hyperglycemia is the production 
of AGEs [7], via attachment of reactive carbohydrate groups to 
proteins, lipids, or nucleic acids. These groups tend to impair 
Fig. 1. Pathogenesis of diabetic neuropathy (DN). Metabolic 
interactions vascular factors are involved at all stages of DN. 
Hyperglycemia, dyslipidemia, metabolic syndrome, impaired 
insulin signaling, and growth factor deficiency are correlated 
with the occurrence of neuropathy. Reduced blood flow through 
loss of autonomic nerve functions may contribute to the pro-
gression of DN, and alterations in microvessels, similar to the 
pathogenic neovascularization described in diabetic retinopa-
thy and nephropathy, also are observed in peripheral nerves.
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the biological function of proteins, thus affecting cellular func-
tion. Extracellular AGEs also bind to the receptor for AGE 
(RAGE), initiating inflammatory signaling cascades, activat-
ing NADPH oxidases, and generating oxidative stress. Long-
term inflammatory responses are also triggered by the upregu-
lation of RAGE and activation of nuclear factor-kappaB [7].
Dyslipidemia
Dyslipidemia is more likely to occur in patients with type 2 
diabetes than in patients with type 1 diabetes. Dyslipidemia is 
linked to DN, and several underlying mechanisms have been 
identified. Not only free fatty acids directly cause damage to 
Schwann cells in vitro, but they also have systemic effects such 
as promoting inflammatory cytokine release from adipocytes 
and macrophages. Plasma lipoproteins, especially low density 
lipoproteins (LDLs), can be modified by oxidation or glyca-
tion, and these modified LDLs can bind to extracellular recep-
tors (including the oxidized LDL receptor LOX-1 [lectin-like 
oxidized LDL receptor-1], toll-like receptor, and RAGE), initi-
ating signaling cascades that activate NADPH oxidase and ul-
timately lead to oxidative stress. Additionally, cholesterol can 
be oxidized to oxysterol that may cause apoptosis in neurons 
[4]. 
 Some evidence exists that neuropathy, particularly when it 
involves loss of autonomic control of the cardiovascular sys-
tem, is closely associated with vascular disease factors, includ-
ing obesity, high plasma levels of cholesterol and triglyceride, 
and high blood pressure. In a small study of patients with type 
1 diabetes, cardiac autonomic neuropathy was associated with 
impaired ventricular function but not associated with systemic 
markers of vascular endothelial dysfunction, suggesting that 
vascular disease itself may not directly lead to neuronal injury. 
However, a more thorough examination of risk factors and 
complications in more than 1,400 patients with type 1 diabetes 
revealed that a decreased vibration perception threshold, which 
predicts foot ulceration and amputation, was strongly associ-
ated with a previous history of cardiovascular disease [8]. Fur-
ther work is needed to determine whether elevated lipids have 
direct effects on peripheral neurons and/or Schwann cells.
 Studies of patients with type 2 diabetes more frequently 
demonstrate a correlation between peripheral sensory neu-
ropathy and peripheral vascular disease than studies of pa-
tients with type 1 diabetes. In rodents, a high-fat diet leads to 
accumulation of sorbitol, oxidized lipids and PARP, and acti-
vation of lipoxygenases in peripheral nerves before the devel-
opment of diabetes [9]. Metabolic pathways might mediate 
neuronal injury in dyslipidemia. Cell culture studies suggest 
that downstream of inflammation and oxidative and nitrosa-
tive stress, protein damage may lead to mitochondrion-medi-
ated activation of cell death mechanisms in neurons. These 
molecular modifications also activate the endoplasmic reticu-
lum unfolded-protein response in many cell types, which can 
lead to cell death through endoplasmic reticulum stress [9].
Impaired insulin signaling
Although insulin does not stimulate glucose uptake in neu-
rons, insulin is essential for general neuronal function. Insulin 
receptors are expressed over neuronal cell bodies in the dorsal 
root ganglion and peripheral axons sustaining the epidermis 
[10]. In fact, it was discovered that neuronal insulin receptors 
are increased after physical injury of peripheral nerves and in 
diabetes. After locally injecting insulin into the hind paw foot-
pad of diabetic mice, nerve fiber density and mechanical sen-
sation improved [10]. Similarly, intranasal insulin administra-
tion in diabetic mice showed a reduction of several patho-
physiology and an increase in sensory nerve fibers in the plan-
tar footpads [11].
 Insulin has been shown to have neurotrophic effects, pro-
moting neuronal growth and survival. Insulin deficiency (type 
1 diabetes) or insulin resistance (type 2 diabetes), which ulti-
mately leads to reduced neurotrophic signaling, is thought to 
contribute to the pathogenesis of DN. In neurons, insulin re-
sistance occurs by inhibition of the phosphatidylinositide 
3-kinase/Akt signaling pathway. Disruption of this pathway 
can also lead to mitochondrial dysfunction and oxidative 
stress, further promoting neuropathy [12].
 In patients with type 1 diabetes, reduction in C-peptide can 
lead to nerve dysfunction in several ways, including reduction 
of sodium potassium adenosine triphosphatase (ATPase) ac-
tivity, endothelial nitric oxide synthase activity, and endoneu-
rial blood flow. Thus, treatment with C-peptide can slow the 
progression of neuropathy in patients with type 1 diabetes [13].
 The mechanisms outlined above lead to many cellular dis-
turbances, including mitochondrial dysfunction, endoplasmic 
reticulum stress, DNA damage, and apoptosis. Another layer 
of complexity is added when considering these processes of 
cell stress or damage occur in several different cell types with-
in the nerves such as neurons (in axons and at nerve termi-
nals), glial cells, and endothelial cells of the microvasculature. 
Furthermore, many of these changes trigger the activation and 
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recruitment of macrophages [14], feeding back into inflam-
matory mechanisms of cell stress and death. Eventually, these 
different forms of cellular stress lead to dysfunction or death 
of the nerve, which may develop as clinical neuropathy.
 Tight glucose control can reduce neuropathy in patients 
with type 1 diabetes, but it is not as effective in patients with 
type 2 diabetes. This disparity is probably related to differences 
in the underlying mechanisms: hyperglycemia and a reduc-
tion in insulin signaling in patients with type 1 diabetes, com-
pared with a combination of hyperglycemia, dyslipidemia, and 
insulin resistance in patients with type 2 diabetes. The pro-
gression of neuropathy between the two types of diabetes may 
differ due to the difference in duration of proneuropathic 
changes before the onset or diagnosis of diabetes. Type 2 dia-
betes does not typically develop rapidly; it occurs after many 
years of obesity and other aspects of the metabolic syndrome. 
Tight glucose control will not necessarily reduce dyslipidemia, 
systemic inflammation, and insulin resistance, and after years 
of these dysfunctions, neuropathy is difficult to halt or reverse. 
Although hyperglycemia contributes to the vicious cycles of 
oxidative stress, inflammation, and cellular damage in patients 
with type 2 diabetes, reducing hyperglycemia alone might not 
be enough to stop the cycle [15].
Metabolic syndrome
Rapid advance in diabetes research has increased our knowl-
edge of how components of the metabolic syndrome damage 
nerves. Along with dyslipidemia and insulin resistance, anoth-
er principal component of the metabolic syndrome, visceral 
adiposity, might be particularly detrimental because it causes 
increased concentrations of free fatty acids in the plasma and 
also induces a proinflammatory state by secreting adipokines 
(contributing to the development of insulin resistance). Hy-
pertension, another aspect of the metabolic syndrome, might 
also be a component contributing to neuropathy, although not 
much is known about the mechanism. The renin-angiotensin 
system, which controls blood pressure, is upregulated in obe-
sity, and might contribute to the development of type 2 diabe-
tes (partly through the promotion of insulin resistance and 
proinflammatory cytokine secretion from adipose tissue) [16]. 
Angiotensin-converting enzyme (ACE) inhibitors have been 
shown to improve DN in animal studies, but the underlying 
mechanism is unclear. Microvascular dysfunction in the nerve 
and decreased endoneurial perfusion are also thought to con-
tribute to neuropathy [17]. Upregulation of the renin-angio-
tensin system might also contribute to neuropathy even 
though this might be regulated by metabolic factors [17].
 These mechanisms are probably linked in several levels. In-
deed, hyperglycemia, insulin resistance, dyslipidemia, system-
ic inflammation, and activation of the renin-angiotensin sys-
tem are all linked together to contribute to a self-perpetuating 
cycle of oxidative stress, inflammatory signals, and disruption 
of normal cellular function. At last, these mechanisms inter-
connect the metabolic syndrome and type 2 diabetes to neu-
ropathy. Thus, neuropathy can possibly develop in the absence 
of diabetes when other aspects of the metabolic syndrome are 
activated. One of the main challenges for researchers is to de-
termine which aspects of the network of mechanisms can be 
blocked to effectively limit or prevent progression of the neu-
ropathy [15].
Growth factor deficiency
In addition to the classical pathogenesis mentioned above, stud-
ies have reported the major pathophysiologic role of neuro-
trophic factors and vascular supply in DN. The two widely con-
sidered downstream consequences of the cellular mechanisms 
are the loss of neurotrophic support and ischemic hypoxia.
 Many representative growth factors have dual effects of be-
ing both neurotrophic and angiogenic. Some examples are vas-
cular endothelial growth factor (VEGF), insulin-like growth 
factor (IGF), nerve growth factor (NGF), brain-derived neuro-
trophic factor (BDNF), and fibroblast growth factor-2 (FGF2, 
also known as bFGF). Recently, the term angioneurin was 
coined to refer to a growth factor, which has both angiogenic 
and direct neurotrophic effects [18]. Studies showed that the 
levels of these angioneurins are decreased in diabetic animals 
and are associated with neural function [19,20]. 
 VEGF, a major angiogenic factor, is a potent selective mito-
genic cytokine for endothelial cells, and it can be induced by 
hypoxia through hypoxia-inducible factor (HIF) 1. In isch-
emic tissues, VEGF induces angiogenesis by stimulating the 
proliferation and migration of endothelial cells, improving tis-
sue ischemia. VEGF also enhances migration and prolifera-
tion of Schwann cells which express kinase insert domain re-
ceptor (KDR) or VEGF receptor (VEGFR) 2. It also promotes 
axonal outgrowth and survival of both the neurons and Sch-
wann cells of superior cervical ganglia and dorsal root ganglia. 
Like VEGF, IGFs induce vessel remodeling and also have neu-
rotrophic effect. IGFs have been shown to promote neurite 
outgrowth of neuroblastoma cells and accelerate regeneration 
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of sensory and motor nerves. IGF1 is widely expressed in cra-
niofacial sensory ganglia, sciatic nerve, spinal cord, sensory 
dorsal root ganglia, and brain, whereas IGF2 is expressed in 
the brain, vascular structures of the nervous system, and mo-
tor neurons. IGF receptors (IGF1R and IGF2R) are present 
throughout neuronal cell bodies, axons, and nerve terminals. 
IGF1 expression is reduced in streptozotocin-induced diabetic 
rats. mRNA and protein expression of both IGF1 and IGF2 are 
decreased in the nerves of streptozotocin-induced diabetic 
rats. Similarly, mRNA and protein expression level of IGF1R 
are decreased in the superior cervical ganglia of streptozoto-
cin-diabetic rats [21]. IGF1 also stimulates Schwann cell mito-
genesis and myelination. These effects may be important for 
interneuronal signaling and peripheral nervous system func-
tion. Sonic hedgehog (SHH) modulates embryonic nerve pat-
terning and development. In diabetic animal, SHH mRNA 
levels are significantly reduced in peripheral nerves. In addi-
tion, overexpression of SHH improves blood flow to ischemic 
nerve and ameliorates nerve function [22]. NGF, a well-known 
neurotrophic factor, was initially identified as a molecule that 
promotes survival and differentiation of sensory and sympa-
thetic neurons. However, current studies also show that NGF 
provides neuroprotective and repair functions. NGF is synthe-
sized by Schwann cells, target cells of sensory and sympathetic 
neurons such as epithelial cells, smooth muscle cells, and fi-
broblasts. NGF homozygous knockout mice do not develop 
proper sympathetic neurons or small neural crest-derived sen-
sory neurons. In addition to these neurotrophic effects, NGF 
directly induces angiogenesis [23].
Vascular deficiency
Maintaining adequate blood supply to nerves is crucial in main-
taining nerve structure and function. Deficiencies in the blood 
supply to neural tissues through vasa nervorum and blood ves-
sel within peripheral nerves largely contribute to pathogenetic 
mechanism of DN. Several mechanisms regarding vascular 
structural changes in ischemia on diabetic nerve have been pro-
posed. The most common abnormality in the structure of dia-
betic vasa nervora is the thickening of basement membrane, 
which is highly correlated with neuropathic severity [24]. In ad-
dition, decrease in nerve conduction velocity (NCV) in diabetic 
rats is preceded by impaired vasodilation in epineurial arteri-
oles, which is partly mediated by ROS production [25]. In con-
trast to constricted epineurial arteriole, endoneurial capillaries 
appear to have a variable patency. Luminal areas of endoneurial 
capillaries were increased in rodent and feline models of DN. 
However, those in human showed mixed results. 
 Studies of blood vessel number or density in the nerves of 
diabetic subjects also showed mixed results. In human, the en-
doneurial capillary density was reported to be higher in early 
diabetic patients than healthy subjects. Conversely, the endo-
neurial capillary density of diabetic patients with established 
neuropathy showed no significant difference to that of healthy 
subjects. However, recent studies have shown decreased func-
tional capillary density using lectin perfusion, which is a meth-
od for measuring capillary density [19]. This discrepancy in 
the number of endoneurial capillaries may arise from different 
methods or markers used in examining capillaries. Studies al-
together suggest that the number of capillary increases in re-
sponse to ischemia in early diabetic condition, and the num-
ber, particularly the functional capillaries, decreases due to im-
paired neovascularization under prolonged diabetic condition 
[19].
 Despite some controversies on the structural aspects, it is 
clear that DN is accompanied by ischemia and hypoxia of mi-
crocirculatory nutrient vessels in nerves [26]. A vicious patho-
genic cycle may develop due to the regulated microcirculation 
by humoral, endothelial, and neural factors. Microcirculatory 
dysfunction results in peripheral nerve dysfunction which re-
sults in abnormal regulation of the microcirculation, ultimate-
ly leading to overall nerve dysfunction. Treatment with vari-
ous vasodilatory agents, such as prostaglandin E1 analogues, 
alpha-adrenergic receptor blockers, ACE inhibitors, angioten-
sin II receptor antagonists, and endothelin receptor antago-
nists in animal models of diabetes has shown to reduce the en-
doneurial blood flow [26].
 Further evidence for the impaired vascularization and isch-
emia in DN shows that there is a decrease in factors that pro-
mote or maintain blood vessel formation in DN (such as 
VEGFs, angiopoietins, IGFs, and NGF). This observation led 
to studies of local delivery of the angiogenic factors VEGF-A 
and VEGF-C into diabetic rats that resulted in increased vasa 
nervora density and NCVs. Additionally, VEGFs have direct 
neurotrophic effects that may contribute to the amelioraton of 
NCVs. For instance, angiogenic medications such as statins 
have shown to improve nerve functions in DN [26].
Neurovascular interaction
One of the main pathogenic factors in the development of DN 
is reduced NBF. Various in vitro and in vivo experiments evi-
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dently show that amelioration of NBF improves nerve func-
tions. Studies reported a decrease in endoneurial blood flow 
on diabetic patients and in presence of hypoxia. Direct mea-
sures of nerve perfusion evidently show that decreased sural 
NBF is strongly associated with DN [27].
 Neurotrophic factors promote the innervation of target tis-
sues during development. For instance, target organs release 
NGF to secure the survival of sympathetic and sensory neu-
rons. Neurotrophic factors, such as BDNF, neurotrophin 3 
(NT3) and NT4, ciliary neurotrophic factor (CNTF), and 
members of the glial cell line-derived neurotrophic factor 
(GDNF) family, also promote the survival of various neuronal 
populations in the developing nervous system [28].
 Consequently, deficiency of these neurotrophic factors can 
cause neurodevelopmental disorders [28]. Diabetes reduces 
BDNF, NGF, and NT3 in peripheral nerves by limiting antero-
grade and retrograde axonal transport. Intrathecal delivery of 
NGF or NT3 improves myelinated fiber innervation in the 
dermal footpad of diabetic mice, and thus, lack of neurotroph-
ic support can affect fiber morphology. Initial discovery of 
neurotrophic factors has shown that some of these molecules 
may regulate angiogenesis. Genetic studies in mice show that 
BDNF is essential factor in maintaining cardiac vessel-wall 
stability during development. Binding to TrkB receptor of en-
dothelial cells, BDNF stimulates angiogenesis in the heart, 
skeletal muscle, and skin. The binding recruits proangiogenic 
bone marrow (BM) cells to stimulate revascularization of isch-
emic limbs. NT4 also has similar activity as it binds to TrkB 
receptor [29]. NGF also stimulates angiogenesis in two ways. 
It stimulates indirectly by increasing the expression of VEGF 
and directly by promoting vascular cell growth. NT3 (through 
binding to TrkC) and leukemia-inhibitory factor both serve as 
inhibitors of the growth of some endothelial cells, whereas 
GDNF and CNTF have no effect on angiogenesis.
 Many common angiogenic factors have recently been dis-
covered to have neuronal activity. Among many factors, evi-
dence indicates that VEGF, one of the main regulators of vessel 
growth in all tissues, also affects many neuronal and glial cell 
types by binding to VEGFRs. Study revealed that hypoxia up-
regulates the expression of VEGF through the binding of HIFs 
to a hypoxia-response element in the promoter of its gene 
[30]. Other VEGF family members, such as VEGFB and 
VEGFC, also have direct effects on neurons, but the roles for 
these proteins in neurodegeneration have not been discovered. 
Platelet-derived growth factors (PDGFs) are the closest homo-
logues of the VEGF family members, and these two families 
even share a common ancestral origin in fruit flies and worms. 
PDGF receptors (PDGFR) are activated to stabilize nascent 
vessels by recruiting smooth-muscle cells around endothelial 
channels. Interestingly, PDGF receptor is not required for 
adult-neuron survival in healthy conditions, but it is neuro-
protective in pathological conditions [31].
 Recent genetic studies reveal effects of other angiogenic fac-
tors in neurodegeneration. Angiogenic properties of angio-
genin (ANG) are mediated by direct effects on endothelial 
cells. In addition, ANG directly stimulates the survival of mo-
tor neurons [32]. There are also a number of other angiogenic 
factors, such as angiopoietin 1 (ANG1), that regulate neuro-
genesis or neuroprotection, but currently, there is no genetic 
evidence supporting effects of angioneurins in neurodegener-
ation. Other molecules, such as FGF2, epidermal growth fac-
tor (EGF), transforming growth factor 1, hepatocyte growth 
factor, IGF1, erythropoietin, and others, have also been impli-
cated in postnatal neuron loss or adult-onset neurodegenera-
tion. Dysfunctional mutations of these factors result in a spec-
trum of histopathological features, including neuron loss, loss 
of function, and degeneration, that develop either spontane-
ously or after injury [32].
 Quiescent endothelial cells require survival signals to cope 
with stressful conditions. Genetic and pharmacological studies 
show that a low level of VEGF is required to maintain the in-
tegrity of quiescent vessels [33]. This supports the hypothesis 
that endothelium-specific loss of VEGF causes generalized 
vessel disintegration with resultant brain infarcts and bleeding 
[33], and it could also explain why VEGF protects vessels in 
peripheral nerves against damage by chemotherapeutic agents. 
FGFs and probably many more angioneurins have similar 
‘vasculo-protective’ effects on quiescent vessels.
 Demyelination is a characteristic of DN. Several angioneu-
rins promote (re)myelination through direct effects on oligo-
dendrocytes, Schwann cells, and their precursors. In vitro, var-
ious angioneurins exert mitogenic effects on oligodendrocytes 
and Schwann cells, and also protect those cells from apoptosis. 
Studies show Pdgfa knockout mice that survived birth develop 
tremor due to severe hypomyelination of neuronal projec-
tions, whereas heterozygous platelet-derived growth factor re-
ceptors (PDGFR) deficient mice develop impaired oligoden-
drocyte-progenitor proliferation and oligodendrocyte regen-
eration in adult models of toxin-induced demyelination [34]. 
The type 1 IGF receptor has a critical role in remyelination; it 
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stimulates the proliferation of oligodendrocyte progenitors. In 
a model of ischemic peripheral neuropathy, VEGF preserves 
axon myelination and promotes axon regeneration through 
the direct stimulation of Schwann-cell migration and prolifer-
ation [35]. 
CELL THERAPIES FOR  DIABETIC 
NEUROPATHY
Growth factors are attractive therapeutic option for DN be-
cause they can promote neuron survival and functional integ-
rity, as well as repair of damaged nerves. Some growth factors 
are angiogenic, and their therapeutic effects are mediated by 
blood vessel growth that supply nutrients and oxygen to 
nerves. Other growth factors, such as NT3, are neurotrophic, 
and their therapeutic effects are via promoting neural regener-
ation and survival. Growth factors, known as angioneurins 
(VEGF, FGF2, NGF, BDNF, IGF1), have both angiogenic and 
neurotrophic properties. The power of these growth factors 
in the treatment of DN was shown by Schratzberger et al. [26]. 
They were the first to inject VEGF encoding plasmids into rat 
and rabbit models of diabetes. The VEGF-treated animals 
showed normalization in NCV, increase in angiogenesis of 
vasa nervora, and increase in nerve fiber density. When the 
plasmid VEGF was applied to human patients, mild, but sta-
tistically significant symptomatic improvement was observed 
in a randomized, double-blinded trial [36]. However, the au-
thors also reported that VEGF therapy was associated with 
adverse side effects that did not reach statistical significance. 
As this study has a relatively small sample size, further study 
is required to conclusively determine the effects of plasmid 
VEGF therapy. Other growth factors, such as IGF1 and IGF2 
have also been studied in animal models of DN and have 
shown protective effects against development of neuropathy 
independent of changes in blood glucose. FGF2 promotes an-
giogenesis and neurogenesis.
 As mentioned, emerging evidence has indicated that angio-
genic factors such as VEGF-A, VEGF-C, SHH, and statin re-
store microcirculation in the affected nerves accompanied by 
functional improvement [37]. On the other hand, lack of neu-
rotrophic factors has been regarded as an important patho-
genic mechanism of DN. Administration of neurotrophic fac-
tors such as NGF, IGF1 and IGF2, CNTF, or GDNF was shown 
to ameliorate DN in animal models [5]. 
 These findings suggest that a therapeutic modality which 
can target both angiogenic and neurotrophic processes may 
have more value in treatment of DN. In this sense, cell therapy 
using stem or progenitor cells has advantages over single gene 
or protein therapy. Cell therapy can increase multiple angio-
genic and neurotrophic factors and potentially supplement 
specific type of cells required for vascular or neuronal regen-
eration. Currently, various circulating or BM cells were shown 
to have favorable effects for treating DN. An advantage of us-
ing circulating or BM-derived cells is that they can be harvest-
ed from a patient’s own peripheral blood (PB) or BM, and re-
introduced back to the patient (Fig. 2). 
Cord blood derived endothelial progenitor cells
EPCs can be isolated from the BM, cord blood, and PB. Many 
experimental studies revealed that EPCs have a potent ability 
for neovascularization and that the transplantation of EPCs 
improves tissue ischemia EPCs isolated from cord blood have 
a greater proliferative potential and a higher cell cycle rate than 
EPCs from other sources, suggesting that cord blood-derived 
EPCs may more effectively contribute to therapeutic vasculo-
genesis [38].
 Naruse et al. [39] have demonstrated that therapeutic neo-
vascularization using human umbilical cord blood-derived 
Fig. 2. Cell therapy for diabetic neuropathy (DN) using adult 
stem or progenitor cells. Candidate adult stem or progenitor 
cells include mononuclear cells (MNCs), endothelial progeni-
tor cells (EPCs), or mesenchymal stem cells (MSCs) from cord 
blood (CB)-, bone marrow (BM)-, or peripheral blood (PB)-
derived cells. Through angiogenic and neurotrophic effects, 
these cells can reverse various functional and histologic mani-
festations of DN. 
Sciatic
nerve
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EPCs reversed DN. EPCs were isolated and expanded on day 7 
of culture from cord blood mononuclear cells (MNCs). Highly 
proliferative cord blood-derived EPCs were maintained even 
in the diabetic condition, claiming that EPCs from cord blood 
have a better proliferative potential and a higher cell cycle rate 
than EPCs from other sources [39]. Unilateral intramuscular 
injection of human cord blood-derived EPCs into hindlimb 
skeletal muscles significantly ameliorated impaired sciatic mo-
tor NCV and sciatic NBF in the EPC-injected side of strepto-
zotocin-induced diabetic nude rats compared with the saline-
injected side of diabetic nude rats. Histological study revealed 
an increased number of microvessels in hindlimb skeletal 
muscles in the EPC-injected side of diabetic rats. These find-
ings suggest that transplantation of EPCs from cord blood may 
be a useful treatment for DN. If one can avoid adverse immu-
nological reaction to allografts, transplantation of cord blood-
derived EPCs with high proliferative capacity may have an ef-
fective treatment of human DN [39].
Peripheral blood mononuclear cells
Blood flow was shown to be improved by implantation of he-
matopoietic MNCs in ischemic myocardium and hindlimb 
muscles [40]. Therapeutic angiogenesis resulting from implan-
tation of blood cells also ameliorated diabetic peripheral neu-
ropathy [41]. PB-derived MNCs (PB-MNCs) contain consider-
ably less EPCs than BM-derived MNCs (BM-MNCs), and im-
plantation of PB-MNCs was less effective in ischemic regions 
than BM-MNCs [42]. However, implantation of PB-MNCs was 
still associated with a significant improvement in collateral per-
fusion and regional function probably as a consequence of sup-
plying angiogenic factors to the ischemic regions [40].
 The recovery of NBF and motor NCV (MNCV) in the strep-
tozotocin-induced diabetic rats was almost equivalent to im-
plantation of either PB-MNCs or BM-MNCs [41], despite the 
BM-MNC fraction containing approximately 10 times more 
EPCs than the PB-MNC fraction. Moreover, immunohisto-
chemical study revealed that no significant increase in vessel 
numbers in the sciatic nerve resulted from implantation of ei-
ther cell fraction. This finding suggests that these implanta-
tions improve NBF and MNCV as a result of an arteriogenic 
effect of angiogenic factors on muscles rather than angiogene-
sis in the sciatic nerve [41].
 PB-MNC and BM-MNC fractions contained similar quan-
tities of VEGF and FGF2, whereas IL1B and TNF levels were 
higher in PB-MNCs than in BM-MNCs [40]. These studies 
indicated VEGF may play a key role in angiogenesis in isch-
emic tissues. VEGF-neutralizing antibody abolished the ef-
fects of both PB-MNCs and BM-MNCs implantations [41], 
suggesting that VEGF may also be responsible for the ob-
served increase in sciatic NBF. It has been reported that PB-
MNCs synthesize and release VEGF as a proinflammatory re-
action [43], and consequently, inflammatory PB-MNCs them-
selves may have a more important role in VEGF production 
than EPCs, resulting in equivalent effects following implanta-
tion of either PB-MNC or BM-MNC fractions. Notwithstand-
ing this limitation, as PB-MNCs and BM-MNCs fractions are 
obtained routinely from donors and then implanted into pa-
tients with hematopoietic diseases, autologous implantation of 
PB-MNCs and BM-MNCs fractions may also provide a safe 
therapeutic strategy for the treatment of diabetic peripheral 
neuropathy.
Bone marrow mononuclear cells
BM-MNCs are derived from BM and isolated using density 
gradient centrifugation. BM-MNCs are heterogeneous cell 
population including lymphocytes, hematopoietic stem/pro-
genitor cells, EPCs, and mesenchymal stem cells (MSCs). BM-
MNCs have been shown to augment neovascularization by in-
creasing a broad range of angiogenic factors, including FGF2, 
VEGF, and angiopoietin 1 in the tissue [44,45]. In animal mo-
dels, transplantation of BM-MNCs into ischemic limbs [45] 
and myocardium [44] increased neovascularization and col-
lateral blood vessel formation. These effects of BM-MNCs 
have also been documented in patients with limb ischemia in 
randomized controlled trials [46]. BM-MNCs are easily isolat-
ed and do not have to be expanded by ex vivo culture. This 
ease of isolation makes BM-MNCs an attractive source of cells 
for therapeutic neovascularization.
 Recent studies have shown favorable therapeutic effects of 
BM-MNCs on experimental DN. Hasegawa and colleagues 
[41] showed that implantation of either PB-MNCs or BM-
MNCs in a rat model of DN improved motor NCV and blood 
flow around the sciatic nerve, which is possibly mediated by 
VEGF secreted from MNCs. This study suggests that BM-
MNCs are more effective than PB-MNCs as BM-MNCs in-
clude significantly more EPCs than PB-MNCs. Recently, Kim 
et al. [20] reported that intramuscularly transplanted BM-
MNCs preferentially localize to the nerves in diabetic rats, es-
pecially around vasa nervorum, and increase expression of 
various angiogenic and neurotrophic factors in the nerves. 
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The vascularity of these nerves improved and NCV levels were 
almost normalized [20]. These studies suggest that the vasa 
nervorum may play a pathogenetic role in both the develop-
ment and reversal of DN. This study further suggested that 
angiogenesis is the central mechanism of BM-MNC-induced 
neovascularization in experimental DN because, from their 
observation, BM-MNCs do not differentiate into, nor fuse 
with, endothelial cells in the nerves at a detectable level.
 More recently, other reported study also showed the trans-
plantation of freshly isolated BM-MNCs alleviated neuropath-
ic pain in the early stage of streptozotocin-induced diabetic 
rats [47]. Mechanical hyperalgesia and cold allodynia in SD 
rats were measured as the number of foot withdrawals to von 
Frey hair stimulation and acetone application, respectively. 
The BM-MNC transplantation significantly ameliorated me-
chanical hyperalgesia and cold allodynia in the BM-MNC-in-
jected side. Furthermore, the slowed MNCV/SNCV and de-
creased sciatic NBF (SNBF) in diabetic rats were improved in 
the BM-MNC-injected side. BM-MNC transplantation im-
proved the decreased mRNA expression of NT3 and number 
of microvessels in the hind limb muscles. There was no dis-
tinct effect of BM-MNC transplantation on the intraepidermal 
nerve fiber density [47]. The immunohistological study re-
vealed that the BM-MNC transplantation increased the num-
ber of microvessels in the ipsilateral soleus muscle. In the sci-
atic nerve, STZ-induced diabetes induced a reduction of the 
NBF and this deficit was recovered by BM-MNC transplanta-
tion. Kim and the colleagues [20] indicated that transplanted 
BM-MNCs preferentially engrafted in the sciatic nerve and 
improved NBF. These results, therefore, suggest that improve-
ment of the blood flow in the tissues including nerve vessels is 
one of the crucial effects of BM-MNC transplantation. This 
study showed that transplantation of BM-MNCs into the uni-
lateral hindlimb skeletal muscles inhibited mechanical hyper-
algesia in the ipsilateral side but not in the contralateral side 
[47]. Two clinical studies supported these observations linking 
painful DN with alterations in blood flow, and demonstrated 
significant benefits of pain relief from the use of vasodilators, 
isosorbide dinitrate spray, and glyceryl trinitrate patches [48]. 
These results with the previous studies [20,39] supported 
showing that autologous transplantation of BM-MNCs could 
be useful for the treatment of painful DN.
Bone marrow-derived mesenchymal stem cells 
MSCs have been reported to secrete various cytokines that ex-
hibit angiogenic and neurosupportive effects. MSCs reside in 
the BM stromal fraction, which provides the cellular microen-
vironment supporting hematopoiesis. Because MSCs have an 
adherent nature, they are expandable in culture, and it is rela-
tively easy to obtain a sufficient number of cells for cell thera-
py. MSCs have recently been shown to differentiate into multi-
lineage cell types and to secrete various cytokines, including 
FGF2 and VEGF. Through these actions, transplantation of 
MSCs has been experimentally reported to be a promising 
strategy for the treatment of ischemic diseases such as myo-
cardial infarction and arteriosclerosis obliterans. Shibata and 
the colleagues [49] showed that MSC transplantation amelio-
rated DN. MSCs were isolated from BM of adult rats and 
transplanted into hind limb skeletal muscles of STZ-induced 
diabetic rats by unilateral intramuscular injection. Four weeks 
after transplantation, VEGF and FGF2 productions in trans-
planted sites, current perception threshold, NCV, SNBF, capil-
lary number to muscle fiber ratio in soleus muscles, and sural 
nerve morphometry were significantly increased in MSC-in-
jected thigh muscles of STZ-induced diabetic rats. Further-
more, colocalization of MSCs with VEGF and FGF2 in the 
transplanted sites was confirmed. STZ-induced diabetic rats 
showed hypoalgesia, delayed NCV, decreased SNBF, and de-
creased capillary number to muscle fiber ratio in soleus mus-
cles, which were all ameliorated by MSC transplantation. Sural 
nerve morphometry showed decreased axonal circularity in 
STZ-induced diabetic rats, which was normalized by MSC 
transplantation. These results suggest that MSC transplanta-
tion could have therapeutic effects on DN through paracrine 
actions of growth factors secreted by MSCs [49]. 
Bone marrow-derived endothelial progenitor cells
The development of vascular system consists of two processes: 
vasculogenesis and angiogenesis. Vasculogenesis refers to the 
de novo formation of blood vessels from EPCs or angioblasts 
that differentiate into endothelial cells, whereas angiogenesis 
is growth of pre-existing vasculature by sprouting of new cap-
illaries through proliferation and migration of endothelial 
cells. Until recently, vasculogenesis was thought to be restrict-
ed to embryonic development, while angiogenesis was consid-
ered to be responsible for neovascularization in embryos and 
adults. This view was challenged with the discovery of BM-de-
rived EPCs, which circulate in adult PB, home to ischemic tis-
sue and incorporate into foci of neovascularization, leading to 
de novo blood vessel formation. 
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 The identity of EPCs is complicated by the complexity of 
the definition and various methods to define the cells. It is now 
apparent that different subsets of peripheral or BM derived 
cells, including hematopoietic stem cells, monocytes and cir-
culating endothelial cells, can differentiate into endothelial-
like cells. BM-derived EPCs in the adult PB express a subset of 
hematopoietic stem cell markers. Specifically, CD34, CD133, 
and VEGF receptor-2 have been proposed as candidate mark-
ers for human EPCs [50]. However, there are no known spe-
cific markers to identify EPCs without cultivation. Ex vivo ex-
panded human EPCs express various endothelial cells markers 
such as CD31, CD34, KDR, vascular endothelial (VE)-cad-
herin, bind lectins, and incorporate Dil-acetylated LDL. The 
origin of EPCs is further obscured by the two distinctive types 
of EPCs arising from different culture methods. “Early EPCs,” 
are mainly derived from MNCs or monocytes and do not pro-
liferate after a few weeks. On the other hand, “late EPCs” form 
colonies after more than 2 weeks in culture, have cobblestone 
morphology, and rapidly proliferate [51]. The distinctive char-
acteristics of these two types of EPCs are reinforced by the dif-
ferent expression of cell surface markers. Early EPCs express 
pan-leukocyte and monocytic/macrophage markers such as 
CD45, CD11b, and CD14 while late EPCs do not. Early EPCs 
are also therapeutically effective in vivo while evidence for 
therapeutic efficacy of late EPCs are limited to date [51].
 Endothelial differentiation of EPCs and whether this differ-
entiation plays a main role in the therapeutic benefit of EPCs 
in recovering damaged tissue function is controversial. Several 
recent studies have demonstrated differentiation of EPCs into 
endothelial lineage cells with incorporation into blood vessels 
[52]. However, other investigators claim that BM-derived cells 
including EPCs do not undergo endothelial differentiation nor 
incorporate into vessel walls [53]. These discrepancies may be 
due to the difference in cell types, the use of different animal 
models or the rigor of the criteria to define endothelial differ-
entiation.
 As mentioned above, cord-blood derived EPCs were effec-
tive for treating DN [39]. This study claimed that mechanisti-
cally, the therapeutic effects are due to the increased differenti-
ation of EPCs into endothelial cells in hindlimb muscles, 
which then led to an increase in SNBF. However, this study did 
not demonstrate the fate of the EPCs in tissues, nor did it ad-
dress the mechanisms by which transplanted EPCs increase 
neovascularization in muscles or nerve. Given that most re-
cent studies have argued against the endothelial differentiation 
of EPCs as a major mechanism for neovascularization, endo-
thelial differentiation does not appear to underlie such magni-
tude of therapeutic effects toward DN [54].
 However, a study by the author’s group reported that local 
transplantation of BM-derived EPCs improved various mani-
festations of experimental DN through dual angiogenic and 
neurotrophic effects on peripheral nerves [19]. This study un-
covered several important mechanistic role of EPCs on DN 
[19]. First, intramuscularly injected EPCs exert therapeutic ef-
fects through direct modulation of nerves, not through mus-
cular neovascularization. Second, the therapeutic effects of 
EPCs are mainly mediated by humoral factors, rather than the 
direct endothelial differentiation. Third, the vasa nervora den-
sity in the sciatic nerves was augmented following the EPC 
treatment. Fourth, intramuscularly injected EPCs preferential-
ly recruited to sciatic nerves, preferentially localized in close 
proximity to vasa nervora, and infrequently differentiated into 
endothelial cells [19]. A majority of engrafted EPCs survived 
in peripheral nerves for at least 12 weeks and sustained expres-
sion of angiogenic and neurotrophic factors. Fifth, EPC trans-
plantation increased proliferation and decreased apoptosis of 
endothelial and Schwann cells. 
 The most unique finding was the direct effect of EPCs on 
peripheral nerves. The study was the first to demonstrate that 
EPCs induce neovascularization directly in nerves [19]. An-
giogenesis could have played a more important role than vas-
culogenesis in the increase of neural neovascularization. This 
neural angiogenesis occurred through upregulation of various 
angiogenic factors in nerves after EPC transplantation. Vari-
ous paracrine factors including VEGF-A, FGF2, BDNF, SHH, 
and stromal cell derived factor-1α were expressed in the pe-
ripheral nerves. These factors have synergistic effects on an-
giogenesis and neuroprotective effects. In fact, this study was 
the first to demonstrate unambiguous dual angiogenic and 
neurotrophic effects of EPCs. This upregulation of various bio-
logical factors may be the critical benefits that cell therapy can 
have over any single protein or gene therapy, enabling the syn-
ergistic effects of multiple neuroangiogenic factors necessary 
for neurovascular recovery.
 Histologically, the author’s study also uncovered novel en-
graftment and retention characteristics of BM-derived cells in 
tissues [19]. Following a series of reports on the short-term 
engraftment of any BM cells in a myocardial infarction model 
[55], the prevailing notion was that adult stem/progenitor cells 
could not sustain their engraftment more than a few weeks. 
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However, the study by Jeong et al. [19] clearly rebutted this no-
tion that BM-EPCs could survive more than 12 weeks in 
nerves. While the EPCs which were directly injected into the 
hindlimb muscles disappeared mostly in the muscles within 
8 weeks, the EPCs robustly survived for more than 12 weeks 
in the sciatic nerves. Interestingly, the study by Naruse et al. 
[39] showed that capillary density, which had decreased in 
hindlimb muscles of diabetic rats at 12 weeks of diabetes, was 
significantly increased after cord-blood EPC treatment. How-
ever, this study indicated that blood flow and capillary density 
in hindlimb were not significantly changed after EPC treat-
ment. This long-lasting cell retention is compatible with the 
observation that EPCs homed to peripheral nerves far more 
preferentially than to muscles. This magnitude of interaction 
between any BM cells and steady-state tissues was not previ-
ously demonstrated in other tissues or organs. This series of 
studies with EPCs or BM-MNCs strongly argue that the en-
graftment characteristics of BM cells depends more on the re-
cipient environment than on the transplanted cells themselves 
[19,20]. This evidence supports that despite the controversy of 
EPCs on blood vessel forming capability in certain models like 
myocardial infarction [54], it is evident that EPCs can play an 
important role in vessel homeostasis and revascularization 
[56]. The distinct properties of BM-derived EPCs such as pe-
ripheral neurotropism, long-term retention, and vascular lo-
calization of EPCs worked together to exert prolonged para-
crine or humoral effects and reversal of various functional and 
pathologic manifestations of DN [19,20,39,41]. 
 
CONCLUSIONS
Diabetes injures peripheral nerves in various distributions. The 
most common pattern is distal sensory polyneuropathy (DSP), 
which is characterized by numbness, tingling, pain, or weak-
ness that affects the nerves in a stocking and glove pattern, be-
ginning in the distal extremities. DSP leads to substantial pain, 
morbidity, and impaired quality of life. Societal, personal, and 
healthcare costs associated with DN are high. Unfortunately, 
few interventions are available for the remediation of nonpain-
ful symptoms, and glucose control is the only proven disease-
modifying intervention for these patients. Although pain is a 
common feature, it is often under-reported and undertreated. 
However, many effective therapies exist for DNP, including 
medicines designed to treat seizures and depression.
 Many areas of research into DN are yet to be fully explored, 
but there are promising lines of investigation that could lead to 
improved prevention and treatment of the disorder. The mag-
nitude of the effect of glucose control on neuropathy is much 
smaller in patients with type 2 diabetes than in those with type 
1 diabetes. In view of this small effect size and the fact that 
many patients with type 2 diabetes continue to develop neu-
ropathy despite adequate glucose control, discovery of modifi-
able risk factors for neuropathy is essential. Components of 
the metabolic syndrome, including prediabetes, are potential 
risk factors for neuropathy, and studies are needed to establish 
whether they are causally related to neuropathy. These lines of 
enquiry will have direct implications for the development of 
new treatments for DN.
 DN is a systemic and progressive disease and its manifesta-
tions can take many years to develop. Cell therapy may not be 
a standard treatment option for all stages of DN because dif-
ferent stages of DN are marked by different structural or func-
tional changes. At present, cell therapy may be applied to those 
patients who suffer from intractable symptoms, acute exacer-
bation, or combined diseases such as diabetic foot ulcers or 
critical limb ischemia.
 Practically, as the safety of autologous BM-derived cells has 
been documented by a number of clinical trials [57], it is high-
ly recommended to advance this strategy into a pilot clinical 
trial for those who are severely affected by DN. Particularly, 
EPCs will be effective in treating DN when combined with dia-
betic wounds or peripheral vascular obstruction as the thera-
peutic effects were already shown in these conditions. Howev-
er, there are a few remaining concerns in cell therapy strategy. 
First, the effectiveness of the patient’s own cells needs to be 
evaluated considering the possibility that BM cells derived 
from diabetic subjects may be impaired in therapeutic poten-
tial. Experiments using the autologous cells derived from dia-
betic subjects are necessary to address these concerns. Howev-
er, although the efficacy of autologous diabetic cells is less po-
tent, there may be still ways to overcome these defects to a cer-
tain extent. One strategy is to enhance their angiogenic and 
neurotrophic effects by culturing cells and activating necessary 
pathways with small molecules or growth factors. Second, the 
long-term effects of cell therapy need to be evaluated. Given 
that DN is a disease progressing over a long time, a single in-
jection of cells may not be enough to maintain the nerve func-
tion over a long period of time. One approach is to implant 
cells repeatedly to maintain their effects. At present, the dura-
tion of the beneficial effects of cell therapy in DN is unknown 
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and a critical issue that requires further investigation. In many 
cases, the first manifestation of DN is a diabetic foot or ulcer 
which sometimes requires an amputation and a long-term care 
and significantly reduces patients’ quality of life. Cell therapy 
in this case can be critical to rescue further tissue loss.
 Cardiovascular autonomic neuropathy (CAN) is associated 
with increased risk of cardiovascular morbidity and mortality 
in diabetic patients [58]. Although CAN is one of the most 
frequently studied complications of diabetes [59] and cell 
therapy has been reported to be effective in improving isch-
emic cardiovascular disease [56] and peripheral neuropathy, 
cell therapy has yet been evaluated in either animal models or 
human patients with CAN. Future studies are required to de-
termine the effects of cell therapy in CAN. 
 Future directions of cell therapy for DN will take steps to-
ward enhancing the potency of candidate cells, using both 
gene and cell therapy, and working with combination of vari-
ous cell types such as those derived from induced pluripotent 
stem (iPS) cells. Once generated, iPS cells can offer a plentiful 
and renewal source of cells that can be induced to differentiate 
into cells of interest [60]. Conclusively, cell therapy may be-
come an innovative alternative therapeutic option for treating 
advanced DN. However, further research is necessary to over-
come some limitations and possible adverse effects of cell 
therapy.
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